Schwartz Pharmaceutical

Schwarz Pharma was a prominent German specialty pharmaceutical company headquartered in Monheim am Rhein, specializing in the development and commercialization of innovative therapies for the central nervous system (CNS), gastrointestinal, and cardiovascular therapeutic areas. The company was particularly recognized for its expertise in advanced drug delivery technologies, most notably transdermal patches. In 2006, Schwarz Pharma was acquired by the Belgian biopharmaceutical leader UCB for approximately €4.4 billion ($5.6 billion), a strategic move that significantly bolstered UCB's neurology franchise. Key products integrated into UCB's portfolio through this acquisition include Neupro (rotigotine) for Parkinson's disease and Vimpat (lacosamide) for epilepsy.